365 related articles for article (PubMed ID: 29520812)
1. Nature's first "atypical opioids": Kratom and mitragynines.
Raffa RB; Pergolizzi JV; Taylor R; Ossipov MH;
J Clin Pharm Ther; 2018 Jun; 43(3):437-441. PubMed ID: 29520812
[TBL] [Abstract][Full Text] [Related]
2. Update on the Pharmacology and Legal Status of Kratom.
Prozialeck WC
J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
[TBL] [Abstract][Full Text] [Related]
3. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.
Henningfield JE; Fant RV; Wang DW
Psychopharmacology (Berl); 2018 Feb; 235(2):573-589. PubMed ID: 29273821
[TBL] [Abstract][Full Text] [Related]
4. Kratom (Mitragyna speciosa): worldwide issues.
Ramanathan S; McCurdy CR
Curr Opin Psychiatry; 2020 Jul; 33(4):312-318. PubMed ID: 32452943
[TBL] [Abstract][Full Text] [Related]
5. G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder.
Gutridge AM; Robins MT; Cassell RJ; Uprety R; Mores KL; Ko MJ; Pasternak GW; Majumdar S; van Rijn RM
Br J Pharmacol; 2020 Apr; 177(7):1497-1513. PubMed ID: 31705528
[TBL] [Abstract][Full Text] [Related]
6. Biosynthesis of kratom opioids.
Kim K; Shahsavarani M; Garza-García JJO; Carlisle JE; Guo J; De Luca V; Qu Y
New Phytol; 2023 Oct; 240(2):757-769. PubMed ID: 37518950
[TBL] [Abstract][Full Text] [Related]
7. Kratom policy: The challenge of balancing therapeutic potential with public safety.
Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: present knowledge and future directions in perspective of pain.
Ramachandram DS; Damodaran T; Zainal H; Murugaiyah V; Ramanathan S
J Basic Clin Physiol Pharmacol; 2019 Oct; 31(1):. PubMed ID: 31665120
[TBL] [Abstract][Full Text] [Related]
9. Risk of death associated with kratom use compared to opioids.
Henningfield JE; Grundmann O; Babin JK; Fant RV; Wang DW; Cone EJ
Prev Med; 2019 Nov; 128():105851. PubMed ID: 31647958
[TBL] [Abstract][Full Text] [Related]
10. Orally active opioid compounds from a non-poppy source.
Raffa RB; Beckett JR; Brahmbhatt VN; Ebinger TM; Fabian CA; Nixon JR; Orlando ST; Rana CA; Tejani AH; Tomazic RJ
J Med Chem; 2013 Jun; 56(12):4840-8. PubMed ID: 23517479
[TBL] [Abstract][Full Text] [Related]
11. Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
Váradi A; Marrone GF; Palmer TC; Narayan A; Szabó MR; Le Rouzic V; Grinnell SG; Subrath JJ; Warner E; Kalra S; Hunkele A; Pagirsky J; Eans SO; Medina JM; Xu J; Pan YX; Borics A; Pasternak GW; McLaughlin JP; Majumdar S
J Med Chem; 2016 Sep; 59(18):8381-97. PubMed ID: 27556704
[TBL] [Abstract][Full Text] [Related]
12. Respiratory effects of oral mitragynine and oxycodone in a rodent model.
Henningfield JE; Rodricks JV; Magnuson AM; Huestis MA
Psychopharmacology (Berl); 2022 Dec; 239(12):3793-3804. PubMed ID: 36308562
[TBL] [Abstract][Full Text] [Related]
13. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
[TBL] [Abstract][Full Text] [Related]
14. Endogenous Opioid Activity as the Mechanism of Action for Mitragyna speciosa (Kratom): The Current State of the Evidence.
Bowe A; Kerr PL
Adv Neurobiol; 2024; 35():287-313. PubMed ID: 38874729
[TBL] [Abstract][Full Text] [Related]
15. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.
Garcia-Romeu A; Cox DJ; Smith KE; Dunn KE; Griffiths RR
Drug Alcohol Depend; 2020 Mar; 208():107849. PubMed ID: 32029298
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic and clinical assessment of kratom.
White CM
Am J Health Syst Pharm; 2018 Mar; 75(5):261-267. PubMed ID: 29255059
[TBL] [Abstract][Full Text] [Related]
17. Kratom Alkaloids: A Blueprint?
Smith KE; Sharma A; Grundmann O; McCurdy CR
ACS Chem Neurosci; 2023 Jan; 14(2):195-197. PubMed ID: 36594896
[TBL] [Abstract][Full Text] [Related]
18. On subclasses of opioid analgesics.
Raffa RB
Curr Med Res Opin; 2014 Dec; 30(12):2579-84. PubMed ID: 25105308
[TBL] [Abstract][Full Text] [Related]
19. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.
Kruegel AC; Gassaway MM; Kapoor A; Váradi A; Majumdar S; Filizola M; Javitch JA; Sames D
J Am Chem Soc; 2016 Jun; 138(21):6754-64. PubMed ID: 27192616
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of Mitragyna speciosa extract, mitragynine, and opioid agonists on thermal nociception in rats.
Carpenter JM; Criddle CA; Craig HK; Ali Z; Zhang Z; Khan IA; Sufka KJ
Fitoterapia; 2016 Mar; 109():87-90. PubMed ID: 26688378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
